Cytosorbents Corporation (CTSO) AI Stock Analysis

Cytosorbents Corporation researches, develops, and commercializes medical devices utilizing a proprietary adsorbent polymer blood purification technology platform. Its flagship product, CytoSorb, functions as an extracorporeal cytokine filter used as adjunctive therapy for sepsis, critical care, and the prevention of perioperative complications during cardiopulmonary bypass surgery. The company also produces VetResQ for veterinary care and CytoSorb-XL for broader therapeutic use. Additionally, its development pipeline includes HemoDefend for blood transfusion purification, K+ontrol for hyperkalemia management, ContrastSorb for contrast-induced nephropathy prevention, BetaSorb for chronic renal failure, and DrugSorb for toxic chemical removal.

Annual revenue fluctuated from $40.1M in FY2021 down to $31.1M in FY2023, before rebounding to $35.6M in FY2024 and $37.1M in FY2025, reflecting a 5-year revenue CAGR of -1.2%. Gross margin stood at 71.5% in FY2025, improving from 59.8% in FY2022. While operating margin improved from -102.8% in FY2023 to -38.4% in FY2025, the company has remained unprofitable, posting net income of -$8.2M and an EPS of -$0.21 in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue growth was 0.2% year-over-year, bringing trailing twelve-month revenue to $37.2M with an operating margin of -24.6% and a net margin of -48.9%.

As of June 30, 2026, Cytosorbents held $4.4M in cash and short-term investments and $26.3M in total debt, resulting in net debt of $21.9M. The company reported negative shareholders' equity of -$751,000 and a current ratio of 0.66. Operating cash flow in FY2025 was -$12.4M, with free cash flow of -$12.5M and capital expenditures of $164,000. Over five years, the company's share count increased 44.5%.

Cytosorbents carries a market capitalization of $13.0M and an enterprise value of $40.5M. The stock trades at a price-to-sales ratio of 0.3x and a forward P/E of 7.2x, below the median of its US-listed Healthcare peers, which trade at 4.1x sales and 17.3x forward earnings. Its price-to-book ratio stands at 11.4x. Over the past year, CTSO shares fell 77.3%, underperforming the S&P 500 (SPY) return of 16.8%. Over a 5-year span, the stock dropped 96.5%, compared to an 83.0% gain for the benchmark.

Wall Street coverage consists of 1 Hold rating, with 0 Buy and 0 Sell ratings. The mean price target is $47.50, which is 1055.7% above the last close price of $4.11. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $38.9M and an EPS of -$4.40. For the next fiscal year, projected revenue is $44.2M with an estimated EPS of $0.00. Cytosorbents logged 0 EPS beats in the last 4 quarters, with the next earnings date scheduled for November 12, 2026.

This page is an AI-written research summary of Cytosorbents Corporation (CTSO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CTSO income statement, CTSO balance sheet, CTSO key metrics, CTSO analyst forecast, CTSO chart. See the CTSO stock overview for the latest quote and news.